Ascendia

  MARKET NEWS

HRA Pharma Rare Diseases Registers the first Cushing’s Syndrome Treatment in Colombia
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Certara Acquires Artificial Intelligence Company That Delivers Predictions to Accelerate Scientific Innovation
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for the Treatment of PCED
Minerva Neurosciences Announces Update on its NDA for the Treatment of Negative Symptoms in Schizophrenia
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

  FEATURED EDITORIAL

  COMPANY PROFILE

Lonza CHI is a preferred global partner to the pharmaceutical, biotech and nutraceutical markets. ​Our pioneering Capsugel capsules and encapsulation technologies help improve speed of development and execution and the match of dosage form performance to ingredients or API application. Our product portfolio and product services for pharmaceutical partners include: Capsules including customizations, Equipment, and Ingredient/API formulation services. We work to prevent illness and promote a healthier ​world by enabling our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight, with world class formulation, manufacturing, scientific expertise and process excellence. ​Click here for more.

  EXCLUSIVE ONLINE CONTENT

Purple Biotech & Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments

Purple Biotech & Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments

Purple  Biotech Ltd. recently announced a research collaboration with Mor Research Applications that provides Purple Biotech first access to early stage oncology product candidates owned by….

Biognosys & Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma & Biomarker Customers

Biognosys & Bruker Form Partnership for Advanced Proteomics CRO Services for Global Biopharma & Biomarker Customers

New strategic partnership aims to broaden access to Biognosys’ leading CRO services and Spectronaut® software tools for unbiased proteomics and epiproteomics….

Oncorus Announces Research Collaboration With Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Oncorus Announces Research Collaboration With Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates

Research collaboration leverages Oncorus’ proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong’s mRNA expertise….

Gilead to Acquire All Remaining Rights to Potential First-In-Class Immunotherapy

Gilead to Acquire All Remaining Rights to Potential First-In-Class Immunotherapy

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 11 – Excipients
January 18 – Drug Delivery